Coadministration of antitubercular and antiretroviral therapy is common in high-burden countries where tuberculosis is the commonest opportunistic infection. Concomitant use of rifampicin and many antiretroviral drugs is complicated by drug-drug interactions caused by the potent induction by rifampicin of genes involved in drug metabolism and transport, which could result in subtherapeutic antiretroviral drug concentrations. This review focuses on drug-drug interactions involving antiretrovirals used in resource-limited settings: the non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz or nevirapine, and ritonavir-boosted protease inhibitors. The reduction of nevirapine concentrations with concomitant rifampicin is greater than with efavirenz, particularly during the lead-in dose period when subtherapeutic concentrations occur in the majority of patients. There is reassuring data on the effectiveness of standard doses of efavirenz with concomitant rifampicin, but the largest cohort study found a higher risk of virological failure with nevirapine. The drug-drug interaction between rifampicin and ritonavir-boosted protease inhibitors is more marked than with the NNRTIs, and therapeutic concentrations have only been achieved with adjusted doses of lopinavir/ ritonavir or with saquinavir/ritonavir (400/400 mg every 12 h). The major barrier to using adjusted dose protease inhibitors with rifampicin is the high rates of hepatotoxicity seen in healthy volunteers. The alternative strategy followed in resource-rich settings is to replace rifampicin with rifabutin, but even if the price of rifabutin were to be dramatically reduced it would be difficult to implement in high-burden countries where standardized antitubercular regimens with fixed-dose combinations are used.
Coadministration of antitubercular and antiretroviral therapy is common in high-burden countries where tuberculosis is the commonest opportunistic infection. Concomitant use of rifampicin and many antiretroviral drugs is complicated by drug-drug interactions caused by the potent induction by rifampicin of genes involved in drug metabolism and transport, which could result in subtherapeutic antiretroviral drug concentrations. This review focuses on drug-drug interactions involving antiretrovirals used in resource-limited settings: the non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz or nevirapine, and ritonavir-boosted protease inhibitors. The reduction of nevirapine concentrations with concomitant rifampicin is greater than with efavirenz, particularly during the lead-in dose period when subtherapeutic concentrations occur in the majority of patients. There is reassuring data on the effectiveness of standard doses of efavirenz with concomitant rifampicin, but the largest cohort study found a higher risk of virological failure with nevirapine. The drug-drug interaction between rifampicin and ritonavir-boosted protease inhibitors is more marked than with the NNRTIs, and therapeutic concentrations have only been achieved with adjusted doses of lopinavir/ ritonavir or with saquinavir/ritonavir (400/400 mg every 12 h). The major barrier to using adjusted dose protease inhibitors with rifampicin is the high rates of hepatotoxicity seen in healthy volunteers. The alternative strategy followed in resource-rich settings is to replace rifampicin with rifabutin, but even if the price of rifabutin were to be dramatically reduced it would be difficult to implement in high-burden countries where standardized antitubercular regimens with fixed-dose combinations are used.
Tuberculosis is the commonest opportunistic infection in HIV-infected patients globally, and is especially common in sub-Saharan Africa, where the majority of new cases of tuberculosis in the highest burden countries are HIVinfected [1] . Access to antiretroviral therapy (ART) is rapidly expanding in resource-limited settings. Although ART reduces the incidence of tuberculosis by approximately 80%, incidence rates remain considerably higher than in the general population [1] . Coadministration of antitubercular therapy and ART is therefore common in high-burden countries. Rifampicin is a key component of antitubercular therapy. Concomitant use of rifampicin and many antiretroviral drugs is complicated by drugdrug interactions caused by the potent induction by rifampicin of many genes involved in drug metabolism and transport [2] , which might result in subtherapeutic antiretroviral drug concentrations with loss of antiviral efficacy and the development of resistance. Overlapping toxicity between drugs used for HIV and tuberculosis could also complicate management. This review focuses on recent information regarding the pharmacokinetics, effectiveness and safety of concomitant use of ART and antitubercular therapy. Only those ART regimens currently recommended by the World Health Organization (WHO) in high-burden countries will be considered, namely a first-line regimen based on the non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz or nevirapine and a second-line regimen based on ritonavir-boosted protease inhibitors [3] . Wherever possible, studies on patients coinfected with HIV and tuberculosis were reviewed in preference to studies examining interactions with rifampicin alone (because interactions might be modified by other antitubercular agents, notably isoniazid, which inhibits many cytochrome P450 enzymes [4] ) or those conducted on healthy volunteers (because diseaserelated factors could alter pharmacokinetics). Tuberculosis immune reconstitution inflammatory syndrome is a further complication of using ART in patients with tuberculosis, but is beyond the scope of this review.
Review
Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries
Introduction

First-line ART regimens
Pharmacokinetics
Nevirapine is metabolized largely by the cytochrome P450 isoenzyme CYP3A4 with some metabolism occurring by CYP2B6, whereas efavirenz is metabolized virtually exclusively by CYP2B6. An in vitro study found that rifampicin induced the expression of CYP2B6 by 8.8-fold and CYP3A4 by 55.1-fold [5] . Therefore, one would anticipate that with concomitant rifampicin the magnitude of the reduction in drug concentrations would be greater with nevirapine than with efavirenz, which is indeed the case.
Pharmacokinetic studies of patients coinfected with tuberculosis and HIV conducted in South Africa [6] , Spain [7] and Thailand [8, 9] have shown significant reductions in the trough concentrations (16-34%) and/or area under the curve (31-40%) of nevirapine when coadministered with rifampicin-based antitubercular therapy. A population pharmacokinetic model predicted that increasing the nevirapine dose by 50% would overcome the enzyme induction from rifampicin [10] . This prediction was supported by an Indian study of seven patients on rifampicin who had trough nevirapine concentrations <3 mg/l; all concentrations increased into the therapeutic range after a 50% increase in the dose of nevirapine [11] . Nevirapine concentrations <3 mg/l are considered subtherapeutic, as this concentration is associated with an increased risk of virological failure [12] .
Two studies, conducted in Malawi and Thailand, evaluated nevirapine concentrations in tuberculosis patients pre-induced with rifampicin during the 2-week nevirapine lead-in dose (200 mg daily) phase. The proportion of patients with subtherapeutic nevirapine concentrations was 59% and 79% at week 2, improving to 14% and 23% on full doses at week 4 for Malawian and Thai patients, respectively [13, 14] . The Thai study included an arm starting nevirapine at full doses (200 mg every 12 h), followed by increasing the dose by 50%. This study was unfortunately stopped early because of a higher rate of hypersensitivity reactions in the high-dose arm, but the difference was not statistically significant.
Concomitant rifampicin has not been shown to consistently reduce efavirenz concentrations. A pharmacokinetic study in 12 participants found decreases in efavirenz area under the curve of 26%
[15] and a retrospective analysis of a therapeutic drug monitoring database found that efavirenz concentrations were significantly lower (by 35%) with concomitant rifampicin [16] , but prospective pharmacokinetic studies conducted in Spain [17] , South African adults [18] and children [19] , and India [20] have not shown significant reductions in efavirenz concentrations.
The WHO and the US Centers for Disease Control and Prevention (CDC) recommend as an option increasing the efavirenz dose by 33% when coadministered with rifampicin [3, 21] . A Thai study reported no difference in efavirenz concentrations in patients randomized to either standard or increased doses of efavirenz with concomitant rifampicin [22] ; however, because their body weights were approximately 50 kg, dose increases continue to be recommended for patients weighing >60 kg [3, 21] . A South African study found no difference in efavirenz concentrations in patients above or below 60 kg taking antitubercular therapy and standard doses of efavirenz [18] , suggesting that adjusted doses are not necessary.
The metabolism of efavirenz is extensively influenced by pharmacogenetic factors. The cytochrome P450 2B6 single nucleotide polymorphism 516G>T, which impairs metabolism, resulting in high efavirenz concentrations, occurs commonly in Southern Africa [18, 23] , West Africa [24] and India [20] . Patients who are homozygous for this polymorphism have high efavirenz concentrations, even in the presence of rifampicin-based antitubercular therapy [18, 20] , and routine efavirenz dose increases in such patients could result in adverse effects.
Effectiveness and tolerability
Only a few studies have compared the effectiveness of NNRTI-based ART in cohorts with and without concomitant rifampicin-based antitubercular therapy. A small Thai study reported no difference in virological suppression with nevirapine-based ART [9] , and a small study from Botswana reported no difference in virological suppression with either efavirenz-or nevirapine-based ART, and no difference in efficacy between efavirenz and nevirapine [25] . A recent large South African study showed that efavirenz was equally effective in patients with and without tuberculosis, but nevirapine was associated with a higher risk of virological failure, although >80% of patients on nevirapine achieved virological suppression at 6 months [26] . Interestingly, patients who started antitubercular therapy when they were established on nevirapine-based ART did not have a higher risk of failure, suggesting that subtherapeutic nevirapine concentrations during the lead-in dose phase [13, 14] accounted for the increased risk of failure. The South African study also showed that efavirenz was more effective than nevirapine in patients without tuberculosis [26] , which a number of other large cohorts have also reported [27] [28] [29] .
A small randomized controlled trial comparing efavirenz with nevirapine in Thai patients on rifampicinbased antitubercular therapy was recently published [30] . The trial found no difference in the proportion of patients with virological suppression at 48 weeks, but had limited power. A larger trial addressing the same question is underway in Mozambique, but results are only expected in 2011.
There is contradictory data on the tolerability of NNRTI-based ART with concomitant antitubercular therapy. Two studies have reported more hepatotoxicity with efavirenz [31] , and with either nevirapine or efavirenz [25] , but two other studies found no significantly increased rate of adverse events with nevirapine [9] , or with either nevirapine or efavirenz [26] .
Research questions
Adequately powered randomized clinical trials should be conducted on first-line ART regimens in patients on rifampicin-based antitubercular therapy to evaluate efficacy and tolerability, and much could be learned from large cohort studies. There is also a need for more studies in children.
There is much more clinical and pharmacokinetic data on the interaction between rifampicin and efavirenz, than with nevirapine. However, as summarized above, the reduction of nevirapine concentrations with rifampicin is greater than that seen with efavirenz. Nevirapine is the most widely used NNRTI in first-line ART regimens in high-burden countries [32] , which is likely to remain the case because it is cheaper than efavirenz and considered to be safer in pregnancy. Thus, the greatest need is for studies on nevirapine. It is our view that further studies should be conducted omitting the lead-in dose of nevirapine, with adequate power to assess the risk of toxicity. It is standard practice to omit the lead-in dose of nevirapine when switching from efavirenz, which is a less potent inducer of cytochrome P450 isoenzymes than rifampicin. A large study of Cambodian patients switching from efavirenz to nevirapine, without the lead-in dose, concluded that there did not appear to be more adverse events than when nevirapine is initiated with increasing doses [33] .
Recommendations
Efavirenz, in standard doses, is the preferred NNRTI for concomitant use with rifampicin. If efavirenz is unavailable or inappropriate (for example, during the first trimester of pregnancy), then nevirapine could be used. Consideration should be given to omitting the lead-in dose of nevirapine, as when switching from efavirenz to nevirapine, together with close monitoring for toxicity.
Second-line ART regimens
Pharmacokinetics
The drug-drug interaction between rifampicin and protease inhibitors is more severe than with NNRTIs. Rifampicin induces both CYP3A4 and the transmembrane efflux pump P-glycoprotein [2] , and protease inhibitors are substrates of both. The trough concentrations of all ritonavir-boosted protease inhibitors at standard doses are reduced by >90% when coadministered with rifampicin [21] . The CDC guidelines on managing drug interactions in the treatment of HIV-related tuberculosis recommends one of two options to deal with the protease-inhibitor-rifampicin interaction [21] . The first and preferred option is to replace rifampicin with rifabutin, which is the only recommendation given in the current US guidelines on managing opportunistic infections [34] . Rifabutin is a much less potent inducer than rifampicin and has minimal effects on ritonavirboosted protease inhibitor concentrations. Rifabutin is currently very expensive, but even if the price of rifabutin were to be dramatically reduced, it would be difficult to implement in high-burden countries where standardized antitubercular regimens are administered by healthcare workers, often using fixed-dose combinations. Furthermore, a recent Cochrane systematic review of rifabutin in tuberculosis concluded that there was insufficient evidence for its efficacy in HIV-infected patients [35] . Finally, the concentrations of rifabutin are markedly increased by ritonavir-boosted protease inhibitors necessitating a dose reduction and administration three times a week [21] , which will be difficult to implement in clinics where daily administration of the other antitubercular drugs is used.
The second option given in the CDC guidelines to compensate for the inducing effect of rifampicin is to increase the dose of the protease inhibitor. This can be achieved by increasing the ritonavir dose to 400 mg every 12 h with either saquinavir [36, 37] or lopinavir [38] , or by doubling the dose of lopinavir/ritonavir [38] . Studies in South African children coinfected with tuberculosis and HIV found that increasing the ritonavir component to give a lopinavir:ritonavir ratio of 1:1 resulted in adequate trough lopinavir concentrations [39] , but doubling the dose of lopinavir/ritonavir (in the usual formulation of 4:1) did not [40] .
Effectiveness and tolerability
We are not aware of any cohort studies comparing the effectiveness of adjusted doses of boosted proteaseinhibitor-based ART in cohorts with and without concomitant rifampicin-based antitubercular therapy, or of any randomized controlled trials.
The major barrier to using adjusted dose protease inhibitors and rifampicin-based antitubercular therapy is hepatotoxicity. Three recent studies in healthy volunteers exploring the interaction between rifampicin and adjusted doses of ritonavir-boosted saquinavir, lopinavir (tablet formulation) and atazanavir, were prematurely terminated because of very high incidences of hepatotoxicity [41] [42] [43] . The study examining the interaction between boosted saquinavir and rifampicin [41] found different rates of hepatotoxicity depending on the sequence in which the drugs were administered: 2 of 14 participants in the arm given boosted saquinavir initially followed by rifampicin, and 9 of 14 participants in the arm given rifampicin initially followed by boosted saquinavir. In the prematurely discontinued lopinavir and atazanavir studies, rifampicin was commenced first. It has been hypothesized [43] that prior induction of the liver enzymes by rifampicin could give rise to high concentrations of toxic intermediate metabolites when the boosted protease inhibitor is introduced.
There are several reasons why the high rates of hepatotoxicity in healthy volunteers might not apply to patients with tuberculosis and HIV. First, in highburden countries boosted protease inhibitors are used in the second-line regimen; therefore, patients will be established on the protease inhibitor before rifampicin is introduced. Second, isoniazid inhibits the cytochrome P450 isoenzyme CYP3A4, which metabolizes protease inhibitors [4] . Inhibition by isoniazid could modulate the inducing effect of rifampicin and result in lower concentrations of toxic protease inhibitor metabolites, which might be responsible for the hepatotoxicity [43] . Third, the risk of hepatotoxicity might be different in HIV-infected patients, as illustrated by the experience of rifampicin plus pyrazinamide for treating latent tuberculosis, which was well tolerated in HIV-infected individuals [44] , but subsequent trials in HIV-uninfected individuals found high rates of hepatotoxicity with this regimen [45, 46] .
There is very little data on the rates of hepato toxicity in patients coinfected with HIV and tuberculosis taking adjusted doses of boosted protease inhibitors: reports indicate a rate of 0 of 15 children on lopinavir [39] and 4 of 20 adults on saquinavir (but with high rates of gastrointestinal intolerance) [37] . Currently no clear recommendation can be made from the limited evidence [21] .
Research questions
The proportion of patients on second-line ART regimens in resource-limited settings is currently small, but will inevitably grow. The most pressing need is for studies investigating the safety and pharmacokinetics of the use of adjusted dose ritonavir-boosted protease inhibitors with rifampicin-based antitubercular therapy in patients rather than in healthy volunteers.
Recommendations
Adjusted doses of protease inhibitors (either increasing the ritonavir dose to 400 mg every 12 h with either saquinavir or lopinavir, or by doubling the dose of lopinavir/ritonavir) should be considered for coadministration with rifampicin only if failure or intolerance of NNRTIs has occurred. Liver function tests should be very closely monitored. Middle income countries should consider substituting rifampicin with rifabutin.
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